ELFP方案治疗晚期胃癌的临床观察

Etoposide, cisplatin, leucovorin and fluorouracil regimen in the treatment of advanced gastric adenocarcinoma

目的 :观察ELFP方案治疗晚期胃癌的疗效和毒副作用。方法 :39例晚期胃癌患者接受PDD 30mg静滴 ,第 1～ 4天 ;VP - 16 10 0mg静滴 ,第 1～ 5天 ;CF 10 0mg静滴 ,第 1～ 5天 ;5 -Fu 75 0mg静滴 ,第 1～ 5天 ;2 1天为 1周期。结果 :可评价疗效患者 31例 ,总有效率 5 8% ,完全缓解率 16 1% ,可评价毒性患者 39例 ,白细胞减少发生率 79 5 % (Ⅲ度～Ⅳ度仅 5 1% ) ,血红蛋白减少和血小板减少发生率分别为 15 4%和 33 3% ,其它毒副反应少见。结论 :ELFP方案治疗晚期胃癌疗效肯定 ,毒性较低 ,值得继续研究。

Objective: To assess the antitumor efficacy and tolerance of the combination of Etoposide(VP 16),Cisplatin(PDD), Leucovorin(CF)and Fluorouracil(5 FU)in advanced gastric adenocarcinoma patient Methods: Between June 1994 and July 1998, 39 patients with gastric adenocarcinoma were treated with PDD 30 mg/day for 4 consecutive days by intravenous infusion(Ⅳ),VP 16 100 mg/day for 5 consecutive days IV, CF 100 mg/day for 5 consecutive days IV,and 5 Fu 750 mg/day for 5 consecutive days Ⅳ,every 3 weeks Results:Thirty one patients were evaluable for efficacy The overall response rate was 58%and the complete response rate was 16 1% Thirty nine patients were evaluable for toxicity Leukopenia was observed in 79 5%of the patients,but grade 3 and 4 toxicity were in only 5 1%of patients Anemia and thrombocytopenia were observed in 15 4%and 33 3%of patients, other side effects were uncommon Conclusions: VP 16,PDD, CF and 5 Fu are effecfive for treatment of advanced gastric adenocarcinoma and worthwhile of further study